Advertisement

Topics

Novartis buy Takeda's dry-eye drug Xiidra for $5.3 billion Gilead struck anticompetitive deals over HIV meds #NHS England pay for Biogen's Spinraza Trials to test long acting #HIV injection and Elin Lilly's migraine drug http://bit.ly/2w5O4mK  #pharmap

07:19 EDT 17 May 2019 | Pharmafile

Novartis buy Takeda's dry-eye drug Xiidra for $5.3 billion Gilead struck anticompetitive deals over HIV meds England pay for Biogen's Spinraza Trials to test long acting injection and Elin Lilly's migraine drug http://bit.ly/2w5O4mK 

Original Article: Novartis buy Takeda's dry-eye drug Xiidra for $5.3 billion Gilead struck anticompetitive deals over HIV meds #NHS England pay for Biogen's Spinraza Trials to test long acting #HIV injection and Elin Lilly's migraine drug http://bit.ly/2w5O4mK  #pharmap

NEXT ARTICLE

More From BioPortfolio on "Novartis buy Takeda's dry-eye drug Xiidra for $5.3 billion Gilead struck anticompetitive deals over HIV meds #NHS England pay for Biogen's Spinraza Trials to test long acting #HIV injection and Elin Lilly's migraine drug http://bit.ly/2w5O4mK  #pharmap"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...